ELMD · NYSEHealthcare: medical devices (home respiratory equipment)November 2026

Electromed Q1 FY27 Update

$27.18
$222m
buy below $37 (unchanged)
Download Full research report (PDF)

This is the 16th consecutive quarter they have increased both our revenue and operating income year-over-year!

This was a great quarter for my thesis. The tests that I set in October were met this quarter. Revenue rose 10.6% and home care revenue rose 17.6%. The smaller channels, which are distributor and hospital channels, fell by 41%. Gross margin is 80%. The two main tests in the October thesis were revenue per rep and the rate of home care growth and this quarter exceeded both. I'm still a bit below analyst expectations for revenue and my thinking is outlined in my report.

← Back to all memos